Episode 85 – Drug Pricing: How The Demise of Chevron Deference and Other Litigation May Impact the Pharmaceutical Industry
Release Date: 09/19/2024
Episode 108 – UK FinReg Focus Areas in 2026
Connected With Latham
In this episode of Connected with Latham, complementing Latham’s “ in 2026” report, London partners and and counsel discuss the key trends for financial services firms in 2026. Amongst other topics, they discuss the Leeds Reforms, the ESG landscape, and enforcement trends. This podcast is provided as a service of Latham & Watkins LLP. Listening to this podcast does not create an attorney client relationship between you and Latham & Watkins LLP, and you should not send confidential information to Latham & Watkins LLP. While we make every effort to assure that the...
info_outline
Episode 107 – Drug Pricing and Market Access: “Think of It as a Loop” — Succeeding in an Evolving Policy Landscape
Connected With Latham
The pharmaceutical industry has seen major legal and policy changes in recent years, from the Inflation Reduction Act to the Trump administration’s aggressive pricing policies. In this episode of Connected With Latham, Mike Domanico, a pharmaceutical industry veteran with experience in Big 4, brand drugs, biosimilars, and generics, and most recently Vice President of Revenue Finance, joins Washington, D.C. partner and associate to discuss how organizations can best respond to the changing environment. As Mike explains, think of meeting the challenge as a loop that connects the business,...
info_outline
Episode 106 – The FDA’s New Playbook: Biosimilars, National Priority Vouchers, and the Plausible Mechanism Pathway
Connected With Latham
Recent FDA actions are reshaping key aspects of drug and biologic development, including the Commissioner’s National Priority Voucher program, the “plausible mechanism” pathway for personalized therapies, and new draft guidance aimed at streamlining biosimilars and interchangeables. Join Washington, D.C. partner and counsel and as they discuss how these moves differ from traditional policy-making, as well as the practical implications for pricing, manufacturing, M&A, and litigation risk in the healthcare and life sciences industry. This podcast is provided as a service of...
info_outline
Episode 105 – Drug Pricing and Market Access: Government Pricing Assessment Expectations and Benefits
Connected With Latham
Government pricing assessments are an important tool to help pharmaceutical manufacturers review their government price reporting function. They can also help uncovering strategic benefits and opportunities. In this episode of Connected With Latham, , Managing Director at Ernst & Young LLP, joins Washington, D.C. partner and associate to explore how these assessments are conducted, the compliance benefits they offer, and the strategic insights they can provide. Also check out our bi-weekly on the website or to receive future editions in your inbox. This podcast is provided...
info_outline
Episode 104 – Drug Pricing and Market Access: Deep Dive on the FDA Commissioner’s National Priority Voucher Program Awards
Connected With Latham
The new FDA Commissioner’s National Priority Voucher (CNPV) pilot program promises to reduce recipients’ application review times from 10-12 months to just 1-2 months. As part of the Trump administration’s push for most favored nation (MFN) pricing, drug affordability is one criterion for vouchers, marking FDA’s entry into the drug pricing fray. In this episode of Connected With Latham, Washington, D.C. partner and counsel explore the in detail and discuss how the accelerated review period might affect launch strategies, whether companies with no voucher will be disadvantaged, and...
info_outline
Episode 103 – Drug Pricing: Takeaways from the Chicago Medicaid Drug Rebate Program Summit
Connected With Latham
Stakeholders from across the healthcare industry — from manufacturers and consultants to outside counsel and government officials — recently convened in Chicago for the Medicaid Drug Rebate Program Summit 2025. In this episode of Connected With Latham, Washington, D.C. partner , counsel , and associate share impressions and key takeaways from the conference, including action items like readying litigation support to address likely future challenges. Also check out our bi-weekly on the website or to receive future editions in your inbox. This podcast is provided as a service of...
info_outline
Episode 102 – EU Data Act: Spotlight on Switching Requirements for Data Processing Services
Connected With Latham
In this episode of Connected With Latham, London partner , Paris partner , and London counsel discuss significant new switching requirements due to take effect for data processing services under the EU Data Act. This podcast is provided as a service of Latham & Watkins LLP. Listening to this podcast does not create an attorney client relationship between you and Latham & Watkins LLP, and you should not send confidential information to Latham & Watkins LLP. While we make every effort to assure that the content of this podcast is accurate, comprehensive, and current, we do...
info_outline
Episode 101 – EU Data Act: Implications for Data Privacy and Cybersecurity
Connected With Latham
In this episode of Connected With Latham, London partner and Frankfurt partner discuss the EU Data Act, and what this means for data privacy and cybersecurity practices. This podcast is provided as a service of Latham & Watkins LLP. Listening to this podcast does not create an attorney client relationship between you and Latham & Watkins LLP, and you should not send confidential information to Latham & Watkins LLP. While we make every effort to assure that the content of this podcast is accurate, comprehensive, and current, we do not warrant or guarantee any of those...
info_outline
Episode 100 – The Leeds Reforms: Implications for UK Financial Services
Connected With Latham
In this episode of Connected with Latham, London partners and discuss the UK government’s plans for the financial services sector, and key takeaways for financial services firms. This podcast is provided as a service of Latham & Watkins LLP. Listening to this podcast does not create an attorney client relationship between you and Latham & Watkins LLP, and you should not send confidential information to Latham & Watkins LLP. While we make every effort to assure that the content of this podcast is accurate, comprehensive, and current, we do not warrant or guarantee any of...
info_outline
Episode 99 – Drug Pricing: Takeaways from the Philadelphia Pricing and Contracting USA Conference
Connected With Latham
Current developments, such as most favored nation (MFN) pricing, grabbed much of the spotlight when key industry stakeholders met in Philadelphia for the Pricing and Contracting USA Conference. In this episode of Connected With Latham, Allan Thoen, Director & Associate General Counsel with Sandoz, joins Washington, D.C. partner and associate to discuss impressions and takeaways from the conference. And read our bi-weekly on the website or to receive future editions in your inbox. This podcast is provided as a service of Latham & Watkins LLP. Listening to this podcast does...
info_outlineRecent Supreme Court decisions, such as the opinions in Loper Bright Enterprises v. Raimondo and Relentless v. Department of Commerce that overruled the long-standing Chevron doctrine, will likely impact how federal agencies interpret ambiguous statutes when regulating the pharmaceutical industry. And in Securities & Exchange Commission v. Jarkesy, the Court established a right to a jury trial for defendants facing civil monetary penalties in agency enforcement actions, which may affect how industry stakeholders respond to enforcement actions. In addition to these cases, which are not specifically focused on the pharmaceutical industry, ongoing manufacturer challenges to the Inflation Reduction Act’s negotiation provisions and to state 340B contract pharmacy laws will likely have a significant impact on the pharmaceutical industry. In this episode of Connected with Latham, Washington, D.C. partner Chris Schott and associate Danny Machado review recent and ongoing cases and explore how they could affect the pharmaceutical industry. Also tune in to the Latham webcast “The Demise of Chevron Deference and Its Impact on the Healthcare and Life Sciences Industries” for a deep dive into Loper Bright Enterprises v. Raimondo and Relentless Inc. v. Department of Commerce.
This podcast is provided as a service of Latham & Watkins LLP. Listening to this podcast does not create an attorney client relationship between you and Latham & Watkins LLP, and you should not send confidential information to Latham & Watkins LLP. While we make every effort to assure that the content of this podcast is accurate, comprehensive, and current, we do not warrant or guarantee any of those things and you may not rely on this podcast as a substitute for legal research and/or consulting a qualified attorney. Listening to this podcast is not a substitute for engaging a lawyer to advise on your individual needs. Should you require legal advice on the issues covered in this podcast, please consult a qualified attorney. Under New York’s Code of Professional Responsibility, portions of this communication contain attorney advertising. Prior results do not guarantee a similar outcome. Results depend upon a variety of factors unique to each representation. Please direct all inquiries regarding the conduct of Latham and Watkins attorneys under New York’s Disciplinary Rules to Latham & Watkins LLP, 1271 Avenue of the Americas, New York, NY 10020, Phone: 1.212.906.1200